PHIO vs. BPTSY, VRPX, GOVX, AGRX, REVB, ATXI, ARAV, NBY, BCEL, and PHAS
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), GeoVax Labs (GOVX), Agile Therapeutics (AGRX), Revelation Biosciences (REVB), Avenue Therapeutics (ATXI), Aravive (ARAV), NovaBay Pharmaceuticals (NBY), Atreca (BCEL), and PhaseBio Pharmaceuticals (PHAS). These companies are all part of the "pharmaceutical preparations" industry.
Biophytis (NASDAQ:BPTSY) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Phio Pharmaceuticals received 35 more outperform votes than Biophytis when rated by MarketBeat users.
Phio Pharmaceuticals' return on equity of 0.00% beat Biophytis' return on equity.
Biophytis has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
0.1% of Biophytis shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Comparatively, 0.8% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Phio Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 402.13%. Given Biophytis' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Biophytis.
In the previous week, Phio Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.
Summary
Phio Pharmaceuticals beats Biophytis on 6 of the 9 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
